56 / 116
Figure2:
Overall survival by prespecified subgroups accordingto baseline characteristics forthe encorafenib plus binimetinib group versusthe vemurafenib group
HR=hazard ratio. LDH=lactatedehydrogenase.ULN=upper limitof normal. ECOG=EasternCooperativeOncologyGroup.
HR (95%CI)
Allpatients
Sex
Men
Women
Age
≥65years
<65years
Race
White
Non-white
Region
NorthAmerica
Europe
Australia
Other
LDH
≤ULN
>ULN
ECOGperformance status
0
1
BRAF
mutation
V600E
V600K
Tumour stage
IIIb, IIIc, IVM1a,or IVM1b
IVM1c
Numberoforgans involvedatbaseline
1
2
3
>3
Brainmetastases
Yes
No
Previous immunotherapy
Yes
No
Previousadjuvanttherapy
Yes
No
1
0·1
10
Favours vemurafenib
Favours encorafenib plus binimetinib
Encorafenibplus
binimetinib (n/N)
Vemurafenib
group (n/N)
105/192
115/192
77/192
60/192
132/192
181/192
11/192
17/192
156/192
5/192
14/192
137/192
55/192
139/192
53/192
170/192
22/192
84/192
108/192
47/192
58/192
45/192
42/192
9/192
182/192
8/192
184/192
49/192
143/192
127/191
111/191
80/191
51/191
140/191
168/191
23/191
17/191
153/191
6/191
15/191
139/191
52/191
140/191
51/191
168/191
23/191
84/191
107/191
45/191
59/191
42/191
45/191
3/191
188/191
7/191
184/191
48/191
143/191
0·61 (0·47–0·79)
0·70 (0·51–0·98)
0·57 (0·37–0·87)
0·63 (0·46–0·86)
0·71 (0·44–1·15)
0·64 (0·49–0·84)
0·89 (0·38–2·09)
0·54 (0·22–1·36)
0·65 (0·48–0·86)
0·54 (0·10–2·98)
0·93 (0·37–2·26)
0·51 (0·36–0·71)
0·95 (0·63–1·43)
0·68 (0·50–0·93)
0·53 (0·34–0·85)
0·70 (0·53–0·92)
0·31 (0·13–0·74)
0·70 (0·46–1·07)
0·59 (0·43–0·83)
0·65 (0·35–1·19)
0·63 (0·39–1·03)
0·50 (0·29–0·84)
0·85 (0·52–1·38)
1·09 (0·22–5·48)
0·63 (0·49–0·82)
0·46 (0·13–1·64)
0·65 (0·50–0·85)
0·83 (0·49–1·41)
0·60 (0·44–0·81)
Análisis subgrupos SG
Encorafenib + Binimetinib vs Vemurafenib
Dummer R,
et al.
Lancet Oncol 2018